Skip to main content
SpringerLink
Log in
Book cover

The Kidney and Hypertension in Diabetes Mellitus pp 375–383Cite as

Clinical Trials in Overt Diabetic Nephropathy

  • Chapter

  • 108 Accesses

Abstract

There is only limited data available regarding how overt diabetic nephropathy should be treated to arrest the progressive decline in renal function. There is agreement on that antihypertensive treatment should be aggressive and that ACE-inhibitors offers an advantage but other interventions, such as improved metabolic control is still controversial. In non-diabetic renal disease, intensive antihypertensive treatment adds only little benefit [1]. In contrast to this, several studies have shown that aggressive antihypertensive treatment is probably the most important factor to determine the rate of decline in kidney function in diabetic nephropathy. The evidence that antihypertensive treatment can preserve renal function is based on the much reduced rate of renal disease progression after effective blood pressure control [2,3]. These studies compare the rate of decline in glomerular filtration rate during intervention with retrospective data. This is not ideal since uncontrolled factors might influence the outcome. However, the effect of antihypertensive treatment is so profound that it is obviously very important for the kidney in diabetic nephropathy. Anyone that treats these patients observe that end-stage renal failure is postponed by antihypertensive treatment and that the disease runs an accelerated course during uncontrolled hypertension. It is a generally held opinion that once established, overt diabetic nephropathy does not benefit from more intense blood-glucose control.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G. The effect of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med 1993; 330: 877–874.

    Article  Google Scholar 

  2. Parving H-H, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. BMJ 1987; 294: 1443–1447.

    Article  CAS  PubMed  Google Scholar 

  3. Mogensen CE. Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment. Scand J Clin Lab Invest 1976; 36: 383–388.

    Article  CAS  PubMed  Google Scholar 

  4. Björck S, Nyberg G, Mulec H, Granerus G, Herlitz H, Aurell M: Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. BMJ 1986; 293: 467–470.

    Article  Google Scholar 

  5. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456–1462.

    Article  CAS  PubMed  Google Scholar 

  6. Taguma Y, Kitamoto Y, Futaki G, Ueda H, Monma H, Ishizaki M, Takahashi H, Sekino H, Sasaki Y: Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 1985; 313: 1617–1620.

    Article  CAS  PubMed  Google Scholar 

  7. Rudberg S, Aperia A, Freyschuss U, Persson B. Enalapril reduces microalbuminuria in young normotensive type 1 (insulin-dependent) diabetic patients irrespective of its hypotensive effect. Diabetologia 1990; 33: 470–476.

    Article  CAS  PubMed  Google Scholar 

  8. Elving LD, Wetzels JFM, de Nobel E, Hoitsma AJ, Berden JHM. Captopril acutely lowers albuminuria in normotensive patients with diabetic nephropathy. Am J Kidney Dis 1992; 20: 559–563.

    CAS  PubMed  Google Scholar 

  9. Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection, Kidney Int 1992; 41: 912–919.

    Article  CAS  Google Scholar 

  10. Holdaas H, Hartmann A, Lien MG, Nilsen L, Jervell J, Fachald P, Endresen L, Djøseland O, Berg KJ. Contrasting effects of lisinopril and nifidepine on albuminuria and tubular transport functions in insulin dependent diabetics with nephropathy. J Int Med 1991; 229: 163–170.

    Article  CAS  Google Scholar 

  11. Gansevoort RT, Apperloo AJ, Heeg JE, De Jong PE, De Zeeuw D. The antiproteinuric effect of antihypertensive agents in diabetic nephropathy. Arch Int Med 1992; 152: 2137–2138.

    Article  CAS  Google Scholar 

  12. Björck S, Mulec H, Johnsen SA, Nordén G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992; 304: 339–343.

    Article  PubMed  Google Scholar 

  13. Stornello M, Valvo EV, Scapellato L. Comparative effects of enalapril, atenolol and chlorothalidone on blood pressure and kidney function of diabetic patients affected by arterial hypertension and persistent proteinuria. Nephron 1991; 58: 52–57.

    Article  CAS  PubMed  Google Scholar 

  14. Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann Int Med 1993; 118: 129–138.

    Article  CAS  PubMed  Google Scholar 

  15. Mulec H, Johnsen S-A, Björck S. Long-term enalapril treatment in diabetic nephropathy. Kidney Int 1994; 45: Suppl. 45: S–141–S–144.

    Google Scholar 

  16. Parving H-H, Hommel E, Smidt UM. Protection of kidney function and decreaseatrialnatriuretic peptide release and action and on albumin excretion rate in hypertensive insulin-dependent diabetic patients. Am J Hypertens 1992.

    Google Scholar 

  17. Ferder L Daccordi H, Panzalis M, Inserra F. Angiotensin converting enzyme inhibitors versus calcium antagonists in the treatment of diabetic hypertensive patients. Hypertension 1992; 19: Suppl. 2: II–237–II–242.

    Google Scholar 

  18. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Int Med 1993; 118: 577–581.

    Article  CAS  PubMed  Google Scholar 

  19. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–986.

    Article  Google Scholar 

  20. Microalbuminuria collaborative study group: Intensive therapy and progression to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria. BMJ 1995; 311: 973–977.

    Article  Google Scholar 

  21. Krolewski AS, LMB Lafel, Krolewski M, Quinn M and Warram JH. Glycosylated haemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 1995; 332: 1251–1255.

    Article  CAS  PubMed  Google Scholar 

  22. Mulec H, Blohmé G, Kullenberg K, Nyberg G, Björck S. Latent overhydration and nocturnal hypertension in diabetic nephropathy. Diabetologia 1995; 38: 216–220.

    Article  CAS  PubMed  Google Scholar 

  23. Heeg JE, De Jong PE, van der Hem GK, de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989; 36: 272–279.

    Article  CAS  PubMed  Google Scholar 

  24. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolese M, Ponticelli C, Ritz E, Zucchelli P, the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Effect of angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939–945.

    Article  CAS  PubMed  Google Scholar 

  25. Bennet PH, Haffner S, Kasiske BL, Keane WF, Mogensen CE, Parving H-H, Steffes MW, Striker GE. Diabetic renal disease recommendations. Am J Kidney Dis 1995; 25: 107–112.

    Article  Google Scholar 

  26. Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving H-H, Passa P, Steffes MW, Striker GE, Viberti GC. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995; 346: 1080–1084.

    Article  CAS  PubMed  Google Scholar 

  27. Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet 1995; 346: 1403–1407.

    Article  CAS  PubMed  Google Scholar 

  28. Rossing P, Tarnow L, Boelskifte S, Jensen BR, Nielsen FS, Parving H-H. Impact of Nisoldipine and Lisonopril on kidney function in hypertensive IDDM subjects with diabetic nephropathy (Abstract). Diabetologia 1996; 39: Suppl. 1: A308.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Njurmottagningen, Sahlgrenska sjukhuset, Göteborg, Sverige

    Staffan Björck

Authors
  1. Staffan Björck
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medical Department M (Diabetes & Endocrinology), Aarhus Kommunehospital University Hospitals in Aarhus, Aarhus C, Denmark

    Carl Erik Mogensen

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer Science+Business Media New York

About this chapter

Cite this chapter

Björck, S. (1996). Clinical Trials in Overt Diabetic Nephropathy. In: Mogensen, C.E. (eds) The Kidney and Hypertension in Diabetes Mellitus. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-6749-0_37

Download citation

  • DOI: https://doi.org/10.1007/978-1-4757-6749-0_37

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4757-6751-3

  • Online ISBN: 978-1-4757-6749-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation